Retatrutide (LY3437943) is a first-in-class triple-receptor agonist peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. Developed by Eli Lilly, it represents a generational advance over single-agonist (semaglutide) and dual-agonist (tirzepatide) compounds — and its Phase 2 clinical data, published in The New England Journal of Medicine, produced the highest weight reduction ever recorded in an obesity trial.

This guide covers retatrutide’s unique triple-agonist mechanism, published clinical trial data, how it compares to its predecessors, and practical research information.

The Triple-Agonist Mechanism

Every incretin-based peptide before retatrutide worked by reducing energy intake — making subjects eat less through appetite suppression and delayed gastric emptying. Retatrutide does this too, but adds something fundamentally new: it also increases energy expenditure. This dual-action approach (eat less + burn more) is what distinguishes it mechanistically and may explain its superior clinical outcomes.

GLP-1 Receptor Activation

The GLP-1 component suppresses appetite through central nervous system signaling, delays gastric emptying (creating prolonged satiety), and promotes glucose-dependent insulin secretion. This is the same mechanism that made semaglutide effective, and retatrutide retains it fully.

GIP Receptor Activation

The GIP (glucose-dependent insulinotropic polypeptide) receptor component enhances insulin secretion beyond what GLP-1 alone achieves and appears to influence lipid metabolism and adipose tissue function. This is the same addition that made tirzepatide more effective than semaglutide, and retatrutide retains it as well.

Glucagon Receptor Activation — The Breakthrough

The glucagon receptor component is retatrutide’s defining innovation. Glucagon receptor activation stimulates hepatic lipolysis (fat breakdown in the liver), increases fatty acid oxidation (burning fat for energy), elevates basal energy expenditure (higher resting metabolic rate), promotes thermogenesis (heat generation from fat metabolism), and drives hepatic glucose output regulation.

This means retatrutide doesn’t just reduce the calories coming in — it actively increases the calories going out. In an energy balance equation (weight change = energy in – energy out), retatrutide pushes both sides simultaneously.

Published Clinical Trial Data

Phase 2 Trial (NEJM, 2023)

The landmark Phase 2 trial, published in The New England Journal of Medicine by Jastreboff et al., enrolled 338 adults with obesity and produced results that exceeded all prior incretin-based therapies:

• 24.2% mean weight loss at the highest dose (12mg) over just 48 weeks — approximately 57.8 pounds in an average participant
• Over 90% of participants in the 12mg group lost at least 10% of their baseline body weight
• Approximately 25% of participants in the 12mg group lost 30% or more of their baseline weight
• No weight-loss plateau was observed at study end — participants were still losing weight when the trial concluded at 48 weeks, suggesting the full efficacy potential had not yet been reached
• Dose-dependent reductions in blood pressure, triglycerides, LDL-cholesterol, and HbA1c

For context: semaglutide achieved ~16% weight loss at 68 weeks, and tirzepatide achieved ~22.5% at 72 weeks. Retatrutide surpassed both — in a shorter timeframe — and hadn’t plateaued.

Phase 3 TRIUMPH Program

Eli Lilly’s Phase 3 program (TRIUMPH trials) is the largest clinical development program for retatrutide. Key results reported to date:

TRIUMPH-4: Average weight loss of approximately 71.2 lbs (32.3 kg) with the 12mg dose over 68 weeks. Concurrent improvements in knee osteoarthritis pain scores were also reported, suggesting benefits beyond weight reduction.

TRANSCEND: Evaluated retatrutide’s effects on metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). Results showed significant liver fat reduction, consistent with the glucagon receptor’s role in hepatic lipid metabolism.

Retatrutide vs. Tirzepatide vs. Semaglutide: How They Compare

Research data allows a direct comparison of the three leading incretin-based compounds. The table below summarizes the key mechanistic and efficacy differences documented in published clinical literature. For a detailed breakdown, see our retatrutide vs tirzepatide comparison guide and three-way semaglutide vs retatrutide vs tirzepatide analysis.

Retatrutide Beyond Weight Loss: Broader Metabolic Research

Published research demonstrates that the compound’s effects extend well beyond body weight reduction. The glucagon receptor component — absent from semaglutide and tirzepatide — appears to drive several additional metabolic benefits that researchers are actively investigating.

Hepatic fat reduction: The TRANSCEND trial documented significant reductions in liver fat content, measured by MRI-PDFF (Proton Density Fat Fraction). The glucagon receptor’s role in hepatic lipid oxidation is thought to be the primary driver. Research published in Cell Metabolism (Coskun et al., 2022) identified the specific molecular pathway responsible for this hepatoprotective effect.

Cardiovascular risk markers: Phase 2 data showed dose-dependent reductions in systolic blood pressure (approximately 6–8 mmHg at 12mg), triglycerides (>40% reduction), and LDL-cholesterol, suggesting potential cardiovascular benefits independent of weight loss. A dedicated MACE (major adverse cardiovascular events) trial is currently underway as part of the Phase 3 program.

Musculoskeletal benefits: TRIUMPH-4 data included patient-reported knee osteoarthritis pain scores, which improved significantly alongside weight reduction. Whether this is mechanical (reduced joint load) or involves direct anti-inflammatory effects remains under investigation.

Researchers interested in related metabolic peptides may also find our guides on tirzepatide research and AOD-9604 fat metabolism research useful for comparative context.

Understanding the Glucagon Receptor’s Role in Energy Balance

The addition of glucagon receptor agonism represents the most mechanistically significant advancement in incretin-based therapy since GIP co-agonism was introduced with tirzepatide. To understand why this matters, it helps to examine how glucagon signaling normally functions in metabolic physiology.

Under fasting conditions, the pancreas releases glucagon to mobilize stored energy — primarily by stimulating the liver to break down glycogen (glycogenolysis) and produce new glucose (gluconeogenesis). Glucagon also signals adipose tissue to release stored fatty acids (lipolysis) and signals the liver to oxidize those fatty acids for ketone production. These are survival mechanisms designed to maintain blood glucose and fuel availability during food scarcity.

The challenge historically was that glucagon receptor agonism causes hyperglycemia when used in isolation — which made it therapeutically counterproductive for metabolic disease management. The key insight that enabled triple-agonist development was that co-administration of GLP-1 receptor agonism counteracts the hyperglycemic effect of glucagon activation while preserving its beneficial effects on fat oxidation and energy expenditure.

Research published in Cell Metabolism (Coskun et al., 2022) demonstrated that this three-way receptor balance achieves something no single-receptor compound can: simultaneous reduction in caloric intake (via GLP-1 and GIP signaling), improvement in insulin sensitivity (via GIP), and elevation in basal metabolic rate (via glucagon). The net result in obese animal models was greater fat mass reduction with better preservation of lean mass compared to either dual-agonist or single-agonist controls.

Phase 3 TRIUMPH Trial Design and Status

The TRIUMPH Phase 3 program represents one of the most comprehensive clinical development programs in metabolic medicine. Eli Lilly registered multiple parallel trials to evaluate the compound across different patient populations and disease indications.

TRIUMPH-1 and TRIUMPH-2: Randomized, double-blind, placebo-controlled studies evaluating weight loss outcomes in adults with obesity (BMI ≥30, or ≥27 with comorbidities) over 68 weeks. These are the pivotal registration trials for a potential obesity indication.

TRIUMPH-3: Evaluated weight loss in adults with type 2 diabetes — a population where incretin-based compounds have shown particular efficacy given the GIP and GLP-1 receptor mechanisms involved in glucose regulation.

TRIUMPH-4: This trial added musculoskeletal outcome measures to the primary weight loss endpoints. The reported 71.2 lb (32.3 kg) average weight loss at 68 weeks with the 12mg dose, alongside improved knee osteoarthritis pain scores (KOOS-PS scale), suggested that the weight-loss benefit may translate into meaningful functional improvements in joint health — an outcome with significant quality-of-life implications.

TRANSCEND: A dedicated metabolic dysfunction-associated steatohepatitis (MASH) trial. Published data showed that the compound significantly reduced liver fat content as measured by MRI-PDFF, with histological improvements in liver fibrosis scores in a subset of participants. This is consistent with the glucagon receptor’s well-documented role in promoting hepatic fatty acid oxidation and reducing hepatic lipid accumulation.

For researchers interested in the broader peptide landscape in metabolic and weight-loss research, our guide to peptides for weight loss research provides a comparative overview of the current evidence base across multiple compound classes.

Comparing Research Access: Prescription vs. Research Compounds

As of 2026, this compound remains in Phase 3 clinical trials and is not available through any pharmacy or prescription pathway. This places it in a distinct category from approved GLP-1 drugs like semaglutide (Wegovy) or tirzepatide (Zepbound), which can only be accessed via prescription for approved indications.

For qualified laboratory researchers, the compound is accessible as a research peptide — manufactured to research-grade specifications, independently tested for purity, and sold exclusively for non-clinical research purposes. PSPeptides offers US-manufactured research-grade material with third-party certificate of analysis (COA) documentation verifying identity and purity. Researchers should review our guide on how to read a peptide COA to understand purity verification standards.

The regulatory landscape for research peptides is evolving. Our 2026 guide to research peptide legality provides current information on the regulatory framework governing research compound access.

Safety Profile

Retatrutide’s safety data from clinical trials shows a profile consistent with the incretin class:

Gastrointestinal effects are the most commonly reported — nausea, diarrhea, vomiting, and constipation occur more frequently at higher doses. These effects are generally dose-dependent, transient, and diminish with continued treatment. This is consistent with semaglutide and tirzepatide.

Cutaneous hyperesthesia (skin sensitivity) was reported in approximately 7% of retatrutide participants versus 1% for placebo — an effect not commonly seen with semaglutide or tirzepatide. This appears to be unique to retatrutide and may relate to the glucagon receptor component.

No clinically significant hypoglycemia was reported. No cases of medullary thyroid cancer or C-cell hyperplasia were observed. Cardiovascular safety outcomes remain under evaluation in ongoing Phase 3 trials.

Molecular Structure

Identifier: LY3437943 | Developer: Eli Lilly | Structure: GIP-based backbone engineered with GLP-1 and glucagon receptor activity, plus a C20 fatty diacid side chain for extended half-life | Administration: Once-weekly subcutaneous injection | Half-life: Approximately 6 days (supporting weekly dosing)

The C20 fatty diacid modification enables albumin binding in circulation, extending the half-life to approximately 6 days and making once-weekly dosing feasible — the same pharmacokinetic strategy used in semaglutide (C18 fatty acid) and tirzepatide (C20 fatty diacid).

Research Protocols: Reconstitution and Storage

For laboratory researchers working with this compound, proper handling is critical to maintaining peptide integrity. The following protocols reflect standard research practice for lyophilized peptide compounds. See our comprehensive peptide reconstitution guide and peptide storage guide for full protocols.

Reconstitution: Lyophilized powder should be reconstituted using bacteriostatic water (0.9% benzyl alcohol). Add the diluent slowly along the vial wall — never inject directly onto the powder. Allow the vial to rest for 5–10 minutes, then gently swirl (do not shake). Standard reconstitution volumes range from 1–2 mL per mg to achieve working concentrations suitable for research dosing.

Storage — lyophilized (dry powder): Store at −20°C for long-term stability (up to 24 months). Short-term storage at 2–8°C is acceptable for up to 30 days if the vial remains sealed. Avoid repeated freeze-thaw cycles, which degrade peptide integrity.

Storage — reconstituted solution: Store at 2–8°C (refrigerated). Use within 28–30 days of reconstitution. Mark the vial with the reconstitution date. Keep away from light to prevent photodegradation.

Research dosing context: Phase 2 trial doses ranged from 0.5mg to 12mg administered subcutaneously once weekly, with dose titration over 16–24 weeks to minimize gastrointestinal side effects. Titration schedules in clinical protocols began at 0.5mg and increased in 4-week intervals.

Current Regulatory Status

Retatrutide is not FDA-approved. It is currently in Phase 3 clinical trials (TRIUMPH program) for obesity and related metabolic conditions. Eli Lilly has not announced an expected approval date, but the Phase 3 program is extensive, suggesting the company is pursuing a broad label.

For researchers, this means retatrutide is available exclusively as a research compound — not through pharmacies or prescription. PSPeptides carries research-grade retatrutide manufactured in the US at 99%+ verified purity.

Buy Retatrutide — Available in 5mg, 10mg, 20mg, 30mg →

What Researchers Should Know About Triple-Agonist Peptide Pharmacokinetics

Understanding the pharmacokinetic profile of triple-agonist compounds is essential for researchers designing dosing protocols. Several characteristics distinguish the pharmacokinetics of this compound class from earlier GLP-1 agents.

Absorption and bioavailability: Following subcutaneous injection, peak plasma concentrations (Cmax) are typically reached within 24–72 hours. The albumin-binding C20 fatty diacid modification ensures sustained plasma levels throughout the weekly dosing interval, maintaining receptor engagement without the concentration peaks and troughs associated with shorter half-life compounds.

Distribution: Plasma protein binding is high (>99%), which limits central nervous system penetration and concentrates receptor engagement at peripheral metabolic targets — the liver, adipose tissue, pancreas, and gut. This peripheral distribution profile is likely responsible for the favorable tolerability profile compared to CNS-penetrant agents.

Metabolism: Like other fatty acid-modified peptides, the compound is primarily metabolized through proteolytic degradation pathways rather than hepatic cytochrome P450 enzymes. This means minimal drug-drug interactions via CYP pathways and no dose adjustment requirements based on CYP phenotype.

Elimination: Terminal elimination follows the approximately 6-day half-life established in Phase 1 studies. Steady-state plasma concentrations are typically achieved within 4–6 weeks of weekly dosing — consistent with the clinical observation that dose titration effects may not be fully apparent until the fourth or fifth week of each dose level.

For researchers who are new to working with lyophilized research peptides, our peptide dosage calculator guide and bacteriostatic water guide provide foundational protocols for safe reconstitution and volume preparation.

Frequently Asked Questions About Retatrutide

How is retatrutide different from semaglutide?

Semaglutide activates only the GLP-1 receptor (appetite suppression). Retatrutide activates three receptors: GLP-1 (appetite), GIP (enhanced insulin/lipid metabolism), and glucagon (increased energy expenditure and fat oxidation). The glucagon component means retatrutide both reduces energy intake AND increases energy output — a mechanistic advantage that published research suggests may explain its superior weight-loss results.

Is retatrutide FDA-approved?

No. Retatrutide is in Phase 3 clinical trials. It is available for laboratory research purposes only and is not available as a prescription medication. Researchers can access it as a research compound through qualified suppliers like PSPeptides, which offers independently verified, US-manufactured retatrutide at 99%+ purity.

What sizes does PSPeptides offer?

Retatrutide is available in 5mg ($39.99), 10mg, 20mg, and 30mg ($119.99) vials, all at 99%+ verified purity with independent third-party testing documentation.

What is the half-life of retatrutide?

Published pharmacokinetic data shows retatrutide has a half-life of approximately 6 days, enabled by its C20 fatty diacid side chain modification which promotes albumin binding in plasma. This extended half-life supports the once-weekly subcutaneous dosing schedule used in all clinical trials to date.

Can retatrutide be stacked with other research peptides?

Published research has not specifically evaluated co-administration of retatrutide with other peptide compounds. Given that it already targets three major metabolic receptors simultaneously, researchers should consult the primary literature carefully before designing multi-compound protocols. Our peptide stacking guide provides a framework for multi-compound research design.

References

1. Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PubMed
2. Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss. Cell Metab. 2022;34(9):1234-1247.e9. PubMed
3. Lilly I. TRIUMPH Phase 3 Clinical Program Overview. ClinicalTrials.gov. ClinicalTrials.gov
4. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3(3):153-165. PubMed

This product is intended for laboratory research use only. Not for human consumption.

PSPeptides — US Made & Shipped | Third-Party Tested | 99%+ Purity | Same-Day Shipping

All PSPeptides products are sold exclusively for research and laboratory use.